Publications

Pembrolizumab and Olaparib in HRD Metastatic Pancreatic Cancer: The POLAR Trial

Park W (Corresponding Author), O’Reilly E, et al.

POLQ-driven repair scars shape the immunogenic landscape of homologous recombination-deficient pancreatic cancer

Park W, Umeda S, Hilmi M, O'Connor C, Sharma R, Tezcan N, Zhang H, Zhu Y, et al.

Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a large contemporary cohort

Keane F, O'Connor C, Moss D, Chou JF, Perry MA, Crowley F, Saxena P, Chan A, et al.

Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma

Keane F, Saadat LV, O'Connor CA, Chou JF, Bowman AS, Xu F, Crowley F, Debnath N, et al.

Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice

Park W, O'Connor CA, Bandlamudi C, Forman D, Chou JF, Umeda S, Reyngold M, Varghese AM, et al.